Peptide therapies have moved from specialist medicine into mainstream conversation, driven by the success of GLP-1 drugs and growing interest in products promoted for recovery, metabolism, healthy aging and cognitive health. But the word “peptide” describes a broad class of compounds—not a single regulatory category—and their legal and scientific status varies substantially.

Some peptide-based medications have completed clinical testing and received FDA approval for specific uses. Semaglutide and tirzepatide products, for example, are approved for defined diabetes or weight-management indications. Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; its prescribing information states that it is not indicated for weight-loss management.

By contrast, widely marketed peptides such as BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon are not FDA-approved drugs. That distinction remains unchanged even if a licensed pharmacy is permitted to compound a product containing one of them. The FDA states it plainly: “Compounded drugs are not FDA-approved.” The agency does not review compounded products for safety, effectiveness or quality before marketing.

Federal policy in this area is governed largely by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, as strengthened by the 2013 Drug Quality and Security Act. Section 503A generally covers patient-specific prescriptions prepared by eligible pharmacies or physicians, while Section 503B establishes a pathway for registered outsourcing facilities operating under additional federal oversight.

The most important recent development is regulatory rather than legislative. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee narrowly recommended adding several previously restricted peptides, including BPC-157 and TB-500, to the 503A Bulks List. The recommendation is nonbinding, and the FDA had not issued a final decision as of September 2026.

The debate reflects competing concerns. Dr. Elizabeth Rebello of the University of Texas MD Anderson Cancer Center told the Associated Press, “I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science.” Supporters counter that allowing licensed pharmacies to prepare these products could move patients away from unverified online vendors and toward clinician-supervised care.

New research has intensified that discussion. A September 2026 analysis identified a 33-fold rise in documented BPC-157 use between 2020 and 2026, while emphasizing major evidence gaps. University of Utah researcher Dr. Flynn McGuire noted, “There was no placebo or untreated comparator,” making reported outcomes difficult to attribute to BPC-157 itself.

The FDA’s final action could reshape access, advertising and pharmacy practice nationwide. Until then, clinics and consumers should be cautious about claims that the peptides have been “cleared” or “approved.” An advisory committee vote can influence policy, but it does not authorize a new medical indication.

For patients, the practical message is straightforward: FDA approval, lawful compounding and medical evidence are three different questions. A peptide’s availability does not establish that it is FDA-approved—or proven safe and effective for a promoted use. Patients should verify the exact product, indication, pharmacy and prescriber, and discuss known and uncertain risks with a qualified healthcare professional.